Loading…
Citius Oncology, Inc. is projected to rise to $0.6127 by 2027, a +3% move from its current price of $0.6254. CTOR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.5981 | $0.6251 | $0.6532 | -0.05% |
| Aug 6 | $0.587 | $0.6247 | $0.6649 | -0.11% |
| Aug 7 | $0.5785 | $0.6244 | $0.6739 | -0.16% |
| Aug 8 | $0.5714 | $0.624 | $0.6815 | -0.22% |
| Aug 9 | $0.5652 | $0.6237 | $0.6882 | -0.27% |
| Aug 10 | $0.5596 | $0.6234 | $0.6944 | -0.33% |
| Aug 11 | $0.5545 | $0.623 | $0.70 | -0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5545 | $0.623 | $0.70 | -0.38% |
| Week 2 | $0.5264 | $0.6206 | $0.7318 | -0.76% |
| Week 3 | $0.5053 | $0.6183 | $0.7565 | -1.14% |
| Week 4 | $0.4879 | $0.6159 | $0.7775 | -1.52% |
| Week 5 | $0.4728 | $0.6135 | $0.7961 | -1.90% |
| Week 6 | $0.4595 | $0.6112 | $0.8131 | -2.27% |
| Week 7 | $0.4474 | $0.6089 | $0.8287 | -2.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Citius Oncology, Inc. is a healthcare company focused on the development and commercialization of targeted oncology therapies.
It also engages in LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
CTOR trades in the healthcare sector with a current price of $0.57 and a market capitalization of $53M. It is ranked 4254 by market listing.
The forecast shows a mix of near-term Neutral and later Bullish years, with notable upside in the later years. For example, the average price in 2029 is $0.7424 with a 30.3 ROI and Bullish sentiment, and the average price by 2050 is $1.94 with a 239.7 ROI and Bullish sentiment.
Overall, the projections depict potential upside over the longer horizon while acknowledging nearer-term uncertainty.
A major floor 32.0% below — a decisive break under it would weaken the trend.
The nearest floor, 14.3% below — buyers have tended to step in here.
The nearest ceiling, 16.7% above — a clean break opens room to run.
A major ceiling 57.8% above — clearing it would confirm fresh momentum.
Key CTOR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTOR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5598 | Buy | $0.5714 | Buy |
| MA 10 | $0.5652 | Buy | $0.5825 | Buy |
| MA 20 | $0.6314 | Sell | $0.6138 | Buy |
| MA 50 | $0.6945 | Sell | $0.6846 | Sell |
| MA 100 | $0.7462 | Sell | $0.7875 | Sell |
| MA 200 | $0.9994 | Sell | $1.05 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.10 | Neutral |
| Stoch RSI (14) | 73.58 | Neutral |
| CCI (20) | -39.68 | Neutral |
| Williams %R (14) | -63.40 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -14.08 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 36.60 | Neutral |
| TRIX (15) | -0.81 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 49.27 | Neutral |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 0.56 | Buy |
| ADX (14) | 21.21 | Sell |
| ATR (14) | 0.02 | Info |
Bearish sentiment dominates the near term. The RSI(14) is 30, and the 50-day simple moving average is $0.757 while the 200-day SMA is $1.06.
The stock sits at a support level of $0.57 with resistance around $0.80; the 30-day price range spans from $0.4005 to $0.8112. Annualized volatility stands at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.493 | $0.5923 | $0.7111 | 0% | Neutral | |
| $0.4616 | $0.6127 | $0.8741 | +3% | Neutral | |
| $0.5205 | $0.7255 | $1.09 | +22% | Bullish | |
| $0.6114 | $0.8879 | $1.40 | +50% | Bullish | |
| $0.6315 | $0.9515 | $1.55 | +61% | Bullish | |
| $0.5558 | $0.8663 | $1.46 | +46% | Bullish | |
| $0.5341 | $0.8597 | $1.49 | +45% | Bullish | |
| $0.5349 | $0.8875 | $1.57 | +50% | Bullish | |
| $0.6037 | $1.03 | $1.87 | +74% | Bullish | |
| $0.7163 | $1.26 | $2.33 | +113% | Bullish | |
| $0.7089 | $1.43 | $2.87 | +141% | Bullish | |
| $1.29 | $2.87 | $6.52 | +385% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.493 | $0.5923 | $0.6972 | -5.29% |
| September 2026 | $0.4696 | $0.5654 | $0.7067 | -4.54% |
| October 2026 | $0.4887 | $0.595 | $0.7564 | +5.23% |
| November 2026 | $0.4778 | $0.5871 | $0.7565 | -1.32% |
| December 2026 | $0.44 | $0.5453 | $0.7111 | -7.13% |
Click any year to see its month-by-month CTOR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CTOR price prediction for 2026 points to an average of $0.5923 (low $0.493, high $0.7111) — a potential gain of 0% on today's $0.6254. A consolidation phase looks the most probable path here.
In 2027, CTOR is projected to trade between $0.4616 and $0.8741, averaging $0.6127 — a potential gain of +3% from today's $0.6254. That is up +3% on the projected 2026 average. Price action looks broadly range-bound.
Citius Oncology, Inc.'s 2028 outlook centres on $0.7255, within a $0.5205 to $1.09 range. That is up +18% on the projected 2027 average. That marks a +22% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CTOR could reach as high as $1.40, with a base case around $0.8879 and support toward $0.6114 — roughly +50% from $0.6254. Momentum favours further upside here.
Expect CTOR to range from $0.6315 to $1.55 through 2030. The $0.9515 average target implies a +61% move from current prices. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CTOR price prediction for 2031 points to an average of $0.8663 (low $0.5558, high $1.46) — a potential gain of +46% on today's $0.6254. Momentum favours further upside here.
In 2032, CTOR is projected to trade between $0.5341 and $1.49, averaging $0.8597 — a potential gain of +45% from today's $0.6254. That is -1% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Citius Oncology, Inc.'s 2033 outlook centres on $0.8875, within a $0.5349 to $1.57 range. That is up +3% on the projected 2032 average. That marks a +50% change versus current levels. Momentum favours further upside here.
By 2034, CTOR could reach as high as $1.87, with a base case around $1.03 and support toward $0.6037 — roughly +74% from $0.6254. Buyers look set to stay in control over this stretch.
Expect CTOR to range from $0.7163 to $2.33 through 2035. The $1.26 average target implies a +113% move from current prices. That is up +22% on the projected 2034 average. Momentum favours further upside here.
The CTOR price prediction for 2040 points to an average of $1.43 (low $0.7089, high $2.87) — a potential gain of +141% on today's $0.6254. Buyers look set to stay in control over this stretch.
In 2050, CTOR is projected to trade between $1.29 and $6.52, averaging $2.87 — a potential gain of +385% from today's $0.6254. That is up +101% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CTOR today (≈ 1,598.976655 CTOR) could be worth
$4,593.03
+$3,593.03 (+359%) by 2050 · US Dollar
Based on the average projected CTOR price of $2.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTORwould be worth at today's price.
$1,000 invested in CTOR on Jul 31, 2025 (≈ 452.48868 CTOR) would be worth
$282.99
-$717.01 (-71.7%) today · 0.28× · US Dollar
Based on a CTOR entry price of $2.21 vs. today's $0.6254.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.562 | $1,112.81 | +11.3% |
| 1 month ago | $0.704 | $888.35 | -11.2% |
| 3 months ago | $0.945 | $661.8 | -33.8% |
| 6 months ago | $1.08 | $579.07 | -42.1% |
| 1 year ago | $2.21 | $282.99 | -71.7% |
| All time (3.6y) ago | $10.09 | $61.98 | -93.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTOR forecast.
Our base-case forecast reaches $1.30 around 2040.
Implied market cap at $1.30: $120.88M
The multi-year forecast shows a mix of Neutral and Bullish years, with several years projecting meaningful upside.
In 2029 the average price is $0.7424 with an ROI of 30.3 and a Bullish sentiment.
In 2030 the average price is $0.821 with an ROI of 44 and a Bullish sentiment.
By 2040 the average price is $0.9194 with an ROI of 61.3 and a Bullish sentiment, and by 2050 the average price is $1.94 with an ROI of 239.7 and a Bullish sentiment. These figures are estimates and carry inherent uncertainty.
Tap a question to reveal the answer.
Avg price $0.7424; min $0.4818; max $1.24; ROI: 30.3; sentiment BULLISH.
Avg price $0.821; min $0.5081; max $1.42; ROI: 44; sentiment BULLISH.
2031 max price $1.22; avg $0.6821; min $0.4039; ROI 19.7; sentiment NEUTRAL.
Avg price $0.9194; min $0.4137; max $2.02; ROI: 61.3; sentiment BULLISH.
Avg price $1.94; min $0.8714; max $4.45; ROI: 239.7; sentiment BULLISH.
Citius Oncology, Inc. Community Discussion
0Share your Citius Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.